Ahmed Elsada

London, ENG SW1A2BU, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma.

Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma.

Journal: Advances in therapy

Published: December 06, 2022

A registry study of relapsed or refractory multiple myeloma pre-exposed to three or more prior therapies including a proteasome inhibitor, an immunomodulatory agent and CD38-targeted monoclonal antibody therapy in England.

A registry study of relapsed or refractory multiple myeloma pre-exposed to three or more prior therapies including a proteasome inhibitor, an immunomodulatory agent and CD38-targeted monoclonal antibody therapy in England.

Journal: EJHaem

Published: April 22, 2021

Population Adjustment Methods for Indirect Comparisons: A Review of National Institute for Health and Care Excellence Technology Appraisals.

Population Adjustment Methods for Indirect Comparisons: A Review of National Institute for Health and Care Excellence Technology Appraisals.

Journal: International journal of technology assessment in health care

Published: June 14, 2019

NICE guidance on enzalutamide for non-metastatic, hormone-relapsed prostate cancer.

NICE guidance on enzalutamide for non-metastatic, hormone-relapsed prostate cancer.

Journal: The Lancet. Oncology

Published: May 20, 2019

NICE guidance on nivolumab with ipilimumab for untreated advanced renal cell carcinoma.

NICE guidance on nivolumab with ipilimumab for untreated advanced renal cell carcinoma.

Journal: The Lancet. Oncology

Published: May 20, 2019

NICE guidance on daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma.

NICE guidance on daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma.

Journal: The Lancet. Oncology

Published: April 15, 2019

NICE guidance on cabozantinib for previously treated advanced renal cell carcinoma.

NICE guidance on cabozantinib for previously treated advanced renal cell carcinoma.

Journal: The Lancet. Oncology

Published: August 13, 2017

NICE guidance on trastuzumab emtansine for HER2-positive advanced breast cancer.

NICE guidance on trastuzumab emtansine for HER2-positive advanced breast cancer.

Journal: The Lancet. Oncology

Published: December 26, 2015

Relative effectiveness assessments of oncology medicines for pricing and reimbursement decisions in European countries.

Relative effectiveness assessments of oncology medicines for pricing and reimbursement decisions in European countries.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: December 17, 2015

NICE guidance on enzalutamide for metastatic hormone-relapsed prostate cancer.

NICE guidance on enzalutamide for metastatic hormone-relapsed prostate cancer.

Journal: The Lancet. Oncology

Published: October 21, 2014

Showing 1-10 of 10

Last Updated: 09/26/2026